Sep. 20 at 12:27 PM
$MGTX I've been trying to find a good proxy for MeiraGTx to get a sense for what we can expect their MC to reach after they get their first GT approved. Krystal Biotech is the perfect example and we should be VERY excited by the following:
-- Krystal is also a gene therapy co
-- Krystal is also vertically integrated
-- Krystal also owns 2 manufacturing
facilities and the combined square
footage is smaller than Meira's
-- Krystal has no JV's for 3rd party
manufacturing
-- Krystal's overall pipeline is smaller
and earlier stage than Meira's
-- Krystal does not have a platform
technology similar to Riboswitch
-- Krystal has 1 approved gene therapy
-- Krystal's 2025 proj. rev = ~
$400M
-- Krystal's current valuation =
$4.73B
There's no question that if Meira is gets its GT for Xerostomia or Parkinson's approved that
$400M annually would be easy to reach and exceed. Note that a
$4.7b MC for Meira would be a share price of ~
$58....
